Biontech and Curevac: A milestone for the biotech future in Rhineland-Palatinate!

Biontech and Curevac: A milestone for the biotech future in Rhineland-Palatinate!

Rheinland-Pfalz, Deutschland - The merger of Biontech and Curevac is seen as an important step for biotechnology in Germany. Minister Schmitt emphasizes the important role of this transaction for the research and innovation location of Rhineland-Palatinate. The takeover should not only achieve strategic goals, but also emphasize the visibility and strength of the biotechnology location. This development follows the international competition, in which MRNA therapies are becoming increasingly important against cancer, and shows the potential of these technologies for health, research and economy.

Biontech plans to take over all stocks from Curevac, which includes a billion dollar volume. The CEO of Biontech, Ugur Sahin, sees the merging of complementary skills and technologies an opportunity to establish new treatment standards for different types of cancer. The federal government does not signal objections to this step and has already initiated the test processes. The financing is through a stock exchange, whereby Curevac shares are rated with a surcharge of over a third.

strategic decisions for the future

The board and the supervisory board of both companies unanimously approved the deal, and the conclusion is expected in 2025. Curevac shares are expected to hold 4-6% of Biontech. Curevac, which was active in the race around a Corona vaccine in the past, moves in a new direction with this takeover. The Federal Government has been holding 13% of Curevac since 2020, and the research site Tübingen should be preserved.

Schmitt also expresses the desire that this step inspires further start-ups, investments and cooperation in the biotech sector. The increase in the international competitiveness of German biotechnology is the focus of the state government, which wants to support research -based added value and innovations with clear framework conditions.

challenges of biotechnology in Germany

Despite the high innovation potential in the biotechnology sector, a current study, published by ESMT Berlin and the Bertelsmann Foundation, sees Germany unable to fully exploit its resources. The report examines the innovation performance of German biotechnology locations and shows that the efficiency of the leading centers has decreased in the past decade with the exception of Munich. The study emphasizes that the recourse to existing resources and targeted promotion of collaborations would be necessary to form a coherent ecosystem.

The biggest challenge for German biotechnology seems to be the weaker knowledge transfer in market maturity applications. The potential to create new solutions is inhibited by fragmentation of the landscape and lack of cooperation. Daniel Posch from the Bertelsmann Foundation speaks of innovation potential that remain "Lost in Translation".

In a rapidly developing health market, the merger of Biontech and Curevac could help increase the dynamics in the biotechnology sector and to strengthen Germany's competitiveness. The focus on research and development, coupled with political initiatives, could be crucial for progress in biotechnology.

For more information about the transaction and the reactions on it, visit the articles on mwvlw Rhineland-Palatinate , Tagesschau and bionity